Interventional Oncology
Michael Soulen, MD
Director Interventional Oncology
Abramson cancer Center, University of Pennsylvania
Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Genentech: Advisory Committee or Review Panel Member (Terminated); Guerbet LLC: Consultant (Ongoing), Research Grant Recipient (Ongoing); Pfizer: Research Grant Recipient (Ongoing); Sirtex Medical: Research Grant Recipient (Ongoing)
Ghassan El-Haddad, MD
Associate Member Interventional Radiology, Head of Radionuclide Therapy Program
Moffitt Cancer Center and Research Institute
Disclosure(s): No relevant disclosure to display
Neuroendocrine tumors are the 2nd-most prevalent GI malignancy. Liver-directed therapies feature prominently in NCCN guidelines and offer years, even decades of benefit in this unique patient population. This session will highlight emerging concepts in the interplay of tumor biology with IO therapies and explore the evolving role of traditional ischemic embolotherapy and radiation-based therapies.
Speaker: Michael C. Soulen, MD – Abramson cancer Center, University of Pennsylvania
Speaker: Ghassan El-Haddad, MD – Moffitt Cancer Center and Research Institute
Speaker: Susan Shamimi-Noori, MD – University of Pennsylvania
Speaker: Nicholas Fidelman, MD (he/him/his) – University Of California San Francisco
Speaker: Etay Ziv, MD PhD – Memorial Sloan Kettering Cancer Center
Speaker: Daniel M. DePietro, MD – Perelman School of Medicine at the University of Pennsylvania
.png)
.jpg)
.png)
.png)
.jpg)
.jpg)
.png)
.png)
.png)